ТЕЙТЕН Ян Йохан Адриан (NL),БЛУМЕРС Йоханнес Мартинус Мария (NL),ДЕ ЛАНГЕ Робертус Петрус Йоханнес (NL)
申请号：
RU2012125827/15
公开号：
RU2012125827A
申请日:
2012.06.20
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. The use of a testosterone analogue and 5-HT1A agonist for the manufacture of a medicament for the treatment of sexual dysfunction, wherein said 5-HT1A is released essentially in one hour and said testosterone analogue is 3.5-5.5 hours before sexual activity. The use of a testosterone analogue, a PDE5 inhibitor and a 5-HT1A agonist for the manufacture of a medicament for the treatment of sexual dysfunction, wherein said 5-HT1A is released in essentially one hour, said PDE5 inhibitor in 1-2 hours and said testosterone analogue in 3.5- 5.5 hours before sexual activity. 3. The use according to claim 1 or 2, wherein said sexual dysfunction is female sexual dysfunction. A pharmaceutical composition comprising a testosterone analogue and a 5-HT1A agonist, wherein said composition is intended to release substantially the indicated 5-HT1A in one hour and the indicated testosterone analogue 3.5-5.5 hours before sexual activity. A pharmaceutical composition comprising a testosterone analogue, a PDE5 inhibitor and a 5-HT1A agonist, wherein said composition is intended to release essentially the indicated 5-HT1A in one hour, said PDE5 inhibitor in 1-2 hours and said testosterone analogue in 3.5- 5.5 hours before sexual activity. 6. A kit comprising at least one pharmaceutical composition comprising a testosterone analogue and at least one composition comprising a 5-HT1A agonist, wherein said kit further includes instructions for administering said compositions. A kit comprising at least one pharmaceutical composition that includes a testosterone analogue, at least one pharmaceutical composition�1. Применение аналога тестостерона и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается по существу за один час и указанный аналог тестостерона - за 3,5-5,5 часов до сексуальной активности.2. Применение аналога тестостерона, ингибитора ФДЭ5 и агониста 5-HT1A для изготовления лекарственного средства для лечени
